BioCorteX

Pioneering in-silico platform that models the microbiome’s impact on drug efficacy, enabling personalized, population-aware drug development and de-risking therapeutic pipelines for global markets

Healthcare & Biotech

AI, Robotics & Automation

Vision

BioCorteX harnesses the world’s largest biology-based knowledge graph—comprised of millions of diverse microbiome samples—to power Carbon Mirror™, an emulator that uncovers critical interactions between bacteria, the immune system, disease states, and pharmaceuticals. This platform reveals how factors such as age, ethnicity, diet, and geography impact drug response, allowing pharmaceutical companies to predict treatment outcomes and tailor therapies to real patient populations. By using advanced in-silico modeling, BioCorteX accelerates and de-risks drug discovery and development, with particular strengths in oncology and antibody-drug conjugates. The actionable insights generated by BioCorteX help ensure that new therapeutics are effective across diverse communities, improving clinical trial success rates and ultimately delivering more personalized medicine worldwide.

Sub-Industries

Drug Development Technology

Pharmacogenomics

Biotech Emulators

Drug-Bacteria Interaction Analysis

Pharmaceutical Innovation

Website

https://biocortex.com/

Location

London, England

Status

Current